Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Clin Cancer Res. 2016 Jun 29;23(3):677–686. doi: 10.1158/1078-0432.CCR-16-0558

Fig 1. Cetuximab induces HER3 expression and activation in HNSCC cell lines.

Fig 1

Cetuximab sensitive UMSCC1-P cells (A) and counterpart resistant UMSCC1-C cells (B) were cultured in medium with 5% FBS. The cells were treated with 2µg/ml cetuximab for the indicated times. CNT indicates the control sample. Both HER3 expression and activation (pHER3) levels were elevated by cetuximab treatment in a time dependent manner (Figure represents 1 of 3 experiments). The average fold increase was determined from 3 individual experiments with standard deviations.